Anti-DNP Polyclonal Antibody

2,4-Dinitrophenol (DNP) is a hapten that induces a strong immune response when attached to proteins or peptides.^1,2 DNP can be incorporated at protein carbonyls via covalent linkage of DNP to carbonyl groups using 2,4-dinitrophenylhydrazine (DNPH) or through site-specific incorporation of unnatural amino acids that contain a DNP functional group.^1,3 Immunization with DNP-modified proteins or tumor cells induces antibody formation in vivo and has been used in the design of vaccines for clearance of disease-causing cells or viruses and induction of autoimmune diseases such as colitis and thyroiditis.^4,5 Cayman’s Anti-DNP Polyclonal Antibody can be used for ELISA, Western blot, and immunoprecipitation applications.

WARNING This product is not for human or veterinary use.

1. Ren, W., Ji, A., Wang, M.X., et al. Expanding the genetic code for a dinitrophenyl hapten. Chembiochem 16(14), 2007-2010 (2015).

2. Jasani, B., Thomas, N.D., Navabi, H., et al. Dinitrophenyl (DNP) hapten sandwich staining (DHSS) procedure. A 10 year review of its principle reagents and applications. J. Immunol. Methods 150(1-2), 193-198 (1992).

3. Yang, T., Zhong, P., Qu, L., et al. Preparation and identification of anti-2, 4-dinitrophenyl monoclonal antibodies. J. Immunol. Methods 313(1-2), 20-28 (2006).

4. Berd, D., Maguire, H.C., Jr., Mastrangelo, M.J., et al. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunol. Immunother. 39(3), 141-147 (1994).

5. Manne, J., Mastrangelo, M.J., and Berd, D. TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. J. Immunol. 169(6), 3407-3412 (2002).